Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatments for non-small cell lung cancer (NSCLC).
• Acquired resistance to EGFR-TKIs presents a significant clinical challenge, limiting long-term efficacy.
• Combination therapy is emerging as a promising strategy to overcome resistance and improve outcomes.

Purpose of the Study:

• To review standard and novel applications of EGFR targets in NSCLC treatment.
• To summarize the mechanisms of EGFR-TKI combination therapies.
• To explore emerging strategies for overcoming EGFR-TKI resistance.

Main Methods:

• Literature review of EGFR-TKI-based combination regimens in NSCLC.
• Summary of clinical trials investigating combination therapies.
• Analysis of novel drug delivery systems, including nanoparticles.

Main Results:

• EGFR-TKI combinations with chemotherapy, anti-angiogenics, and immunotherapy demonstrate significant achievements.
• Clinical trials are expanding indications to EGFR mutation-negative lung malignancies.
• Nanoparticle-based drug delivery systems show potential for enhanced efficacy and targeted release.

Conclusions:

• Combination therapies are essential to overcome inevitable acquired resistance to EGFR-TKIs in NSCLC.
• Further research is needed to elucidate resistance mechanisms and optimize combination strategies.
• Novel drug delivery systems hold promise for future NSCLC treatment paradigms.